

# Long-Term Health Effects: Immune System

Experimental animal data

Jamie DeWitt East Carolina University dewittj@ecu.edu

> 3<sup>rd</sup> Annual PFAS Meeting June 15-17, 2022 in Wilmington, NC

#### Declarations

I currently am funded to study immune system effects of PFAS (sources of funding: North Carolina Policy Collaboratory/NC General Assembly, US EPA/Oregon State University (83948101), NIEHS SRP/NC State University (1 P42 ES031009-01).

I currently am a member of the U.S. EPA PFAS Science Advisory Board and have served as an external peer-reviewer for some of the documents used to support assertions in this slide set.

I often speak publicly about my understanding of PFAS toxicity, serve/have served as a plaintiff's expert witness, advocate for the need to protect the public from their exposures to PFAS, and am a proponent of the essential use concept and the class approach for PFAS management.



What have we learned about effects of PFAS exposure on the immune system?







Information sourced from Agency for Toxic Substances and Disease Registry

## Weighing of the evidence

Table 7. PFOA Main Immune Effects Summary Table										
Category of		Confidence Ratings in		Level of Evidence in						
Immune	Immune	the Body of Evidence		the Body of Evidence						
Response	Outcomes	Human	Animal	Human	Animal	Hazard Conclusion				
Immunosuppression	Antibody response	Moderate	High	Moderate	High	<u>Presumed</u> to be an Immune Hazard to Humans				

Table 9. PFOS Main Immune Effects Summary Table										
Category of		<b>Confidence Ratings in</b>		Level of Evidence in						
Immune	Immune	the Body of Evidence		the Body of Evidence						
Response	Outcomes	Human	Animal	Human	Animal	Hazard Conclusion				
Immunosuppression	Antibody response	Moderate	High	Moderate	High	<u>Presumed</u> to be an Immune Hazard to Humans				



NTP MONOGRAPH ON IMMUNOTOXICITY ASSOCIATED WITH EXPOSURE TO PERFLUOROOCTANOIC ACID (PFOA) OR PERFLUOROOCTANE SULFONATE (PFOS)

## Weighing of the evidence

Reference doses for recommended maximum contaminant level goals (MCLGs) by the U.S. EPA are based on risks of immunotoxicity as represented by impacts of PFAS exposure on vaccine responses in children.

The RfD selected for PFOA is  $1.5 \times 10.9$  mg/kg-day based on the critical effect of decreased serum anti-tetanus antibody concentration in children.

The RfD selected for PFOS is  $7.9 \times 10-9$  mg/kg-day based on the critical effect of decreased serum anti-diphtheria antibody concentration in children.



EXTERNAL PEER REVIEW DRAFT Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water

EXTERNAL PEER REVIEW DRAFT Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctane Sulfonic Acid (PFOS) (CASRN 1763-23-1) in Drinking Water

Note that I am a member of the EPA PFAS Science Advisory Board that was charged with reviewing the processes used to derive these maximum contaminant level goals.

### Weighing of the evidence

#### Toxicological Profile for Perfluoroalkyls

Released May 2021 Last Updated March 2020

#### Statement on Potential Intersection between PFAS Exposure and COVID-19:

CDC/ATSDR understands that many of the communities we are engaged with are concerned about how PFAS exposure may affect their risk of COVID-19 infection. We agree that this is an important question.

CDC/ATSDR recognizes that exposure to high levels of PFAS may impact the immune system. There is evidence from human and animal studies that PFAS exposure may reduce antibody responses to vaccines (Grandjean et al., 2017, Looker et al., 2014), and may reduce infectious disease resistance (NTP, 2016). Because COVID-19 is a new public health concern, there is still much we don't know. More research is needed to understand how PFAS exposure may affect illness from COVID-19.

#### References:

- Grandjean P, Heilmann C, Weihe P, et al. Estimated exposures to perfluorinated compounds in infancy predict attenuated vaccine antibody concentrations at age 5-years. J Immunotoxicol. 2017;14(1):188-195. doi:10.1080/1547691X.2017.1360968
- Looker C, Luster MI, Calafat AM, et al. Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. Toxicol Sci. 2014;138(1):76-88. doi:10.1093/toxsci /kft269
- NTP (National Toxicology Program). 2016. Monograph on Immunotoxicity Associated with Exposure to Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). Research Triangle Park, NC: National Toxicology Program. <u>https://ntp.niehs.nih.gov/ntp/ohat/pfoa\_pfos/</u> pfoa\_pfosmonograph\_508.pdf

DR U.S. Department of Health and Human Services Agency for Toxic Substances and Disease Registry



#### Immune suppression:

A reduced ability of the immune system to respond to a challenge from a level considered normal, regardless of whether clinical disease results (DeWitt et al., 2016). May also include inappropriate inflammatory responses.

#### Immune stimulation:

Inappropriate immune responses to common substances, i.e., allergic hypersensitivity, or responses to self-antigens, i.e., autoimmunity (DeWitt et al., 2016). May also include inappropriate inflammatory responses.



### The "challenge" of a vaccine



In a vaccination, the immune system is challenged and the response to that challenge is measured. It can be evaluated experimentally with "the T cell-dependent antibody response" or "the TDAR."

Image information from: Burleson,

#### Suppressed TDAR in experimental animal models



Oral PFOS exposure in male C57BL/6 mice (60d of exposure) and measurement of **the TDAR**. Oral PFOA exposure in female C57BL/6 mice (15d of exposure) and measurement of **the TDAR**.



Describing PFASinduced immune suppression of understudied PFAS.

FIGURE 3 Evolution of PFEA concentrations in Cape Fear River water at a drinking water intake located approximately 90 mi downstream from a fluorochemical manufacturer



BP—byproduct, PFEA—perfluoroalkyl ether acid, PFMOAA perfluoro-2-methoxyacetic acid, PFO2HxA—perfluoro-3,5dioxahexanoic acid, PFO3OA—perfluoro-3,57-trioxaoctanoic acid, PFO4DA—perfluoro-3,5,7,9-tetraoxadecanoic acid

# We are evaluating the TDAR

of PFAS detected in NC that are toxicologically understudied. These include the "perfluoroether acids" such as GenX, Nafion byproduct 2, PFMOAA, other individual PFEA,s and mixtures of these PFEAs. We often use PFOA as our positive control.

#### Descriptive immunotoxicological

studies are important first steps for uncovering deficits in immune system function.







# How does PFAS exposure affect the TDAR?

One focus of our lab is on B cells, the cells that eventually transform to become antibody-secreting plasma cells and memory B cells.

Future Dr. Krystal Taylor is asking about how PFAS exposure affects subsets

of B cells.

Please visit her poster for more details!





Source of funding: NIEHS/NC State University (1 P42 ES031009-01: NC State University Center for Environmental and Human Health Effects of PFAS).



# How does PFAS exposure affect the TDAR?

One focus of our lab is on B cells, the cells that eventually transform to become antibody-secreting plasma cells and memory B cells.

r. Tracey Woodlief Research Instructor is asking about how PFAS exposure affects how B cells use energy at the level of the mitochondria.





Source of funding: NIEHS/NC State University (1 P42 ES031009-01: NC State University Center for Environmental and Human Health Effects of PFAS).



Stimulated cells (OCR)



B cells are **unstimulated** in culture or **stimulated** with CD40 and IL4. Different lines = different B cell concentrations.

OCR: oxygen consumption rate in real time. A, B, C panels = different concentrations of FCCP (disrupts ATP synthesis).

This tells us about how mitochondria in exposed B cells use energy!

We think PFAS shift energy use in B cells and weaken their ability to shift to antibody-secreting cells.

#### The risk of immunotoxicity from PFAS exposure is real



New Jersey & Michigan MCL for PFOS in drinking water is based on suppression of the TDAR. Six states have RfDs for PFOS based on immune suppression.

#### **European Food Safety Authority**

Tolerable daily intake is based on epidemiological data linking *maternal* PFAS exposure with a decreased antibody responses to vaccines in their breastfed children.

#### ATSDR

Incorporated a modifying factor into its minimal risk level for PFOS citing concerns of the sensitivity of the immune system.

#### EPA

RfD for PFOA/PFOS MCLGs based on risk of immune suppression.

Source of (some) information: Post, 2020.